Your browser does not support the video tag.
Skip to content
home button
  • Resources
    • By Topic
      • Access to Clinical Trials
      • Artificial Intelligence
      • Clinical Trials Landscape
      • Data Collecting + Reporting
      • Ensuring Quality
      • Innovative Trials
      • Patient Engagement
      • Recruitment
      • Regulatory Submissions + Approvals
      • Safety
      • Site Planning
    • By Trial Stage
      • Study Design
        • Innovative Trials
        • Patient Group Engagement
        • Recruitment
      • Study Operations
        • Data Collecting
        • Regulatory Submissions + Approvals
        • Site Planning
  • Case Studies
  • About CTTI
  • Newsroom
  • Membership
  • Annual Report
connect with us
Signup for our Newsletter
  • About CTTI
  • Newsroom
  • Membership
  • Annual Report
Search

CTTI

Clinical Trials Transformation Initiative

Recommendations for Improving Reporting of Unexpected Serious Adverse Events (SAEs) to Investigation New Drug (IND) Investigators

Posted on June 8, 2021February 11, 2025 by Hannah Faulkner

Recommendations for Improving Reporting of Unexpected Serious Adverse Events (SAEs) to Investigation New Drug (IND) Investigators

This entry was posted in Recommendations, SAE Reporting, Safety, Safety Reporting, Study Operations. Bookmark the permalink.

Post navigation

← Evaluating Feasibility of RWD-Supported Recruitment
Recommendations for Good Clinical Practice (GCP) Training for Investigators →

DISCLAIMER: CTTI encourages the use of all materials listed on this site in the pursuit of improving the clinical trials enterprise. Our recommendations, tools, meeting summaries, and more are available to the public for free. We do ask that you acknowledge the source whenever using or referencing CTTI materials. Read our Citation Policy. 

  • About
  • Newsroom
  • Membership
  • Case Studies
  • Contact Us
  • Access to Clinical Trials
  • Artificial Intelligence
  • Clinical Trials Landscape
  • Data Collecting + Reporting
  • Ensuring Quality
  • Innovative Trials
  • Informed Consent
  • Patient Group Engagement
  • Real-World Data
  • Recruitment
  • Regulatory Submissions + Approvals
  • Safety + Protection
  • Site Planning
Sign up for our Newsletter
Log in

© Clinical Trials Transformation Initiative © 2026

terms of use

privacy statement

WordPress is a content management system and should not be used to upload any PHI as it is not an environment for which we exercise oversight, meaning you the author are responsible for the content you post. Please use this system accordingly.